Literature DB >> 23937259

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.

Evy Lobbestael1, Jing Zhao, Iakov N Rudenko, Aleksandra Beylina, Fangye Gao, Justin Wetter, Monique Beullens, Mathieu Bollen, Mark R Cookson, Veerle Baekelandt, R Jeremy Nichols, Jean-Marc Taymans.   

Abstract

A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser910, Ser935, Ser955 and Ser973, is important for PD (Parkinson's disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for disease-modifying PD therapy. Despite this importance of LRRK2 dephosphorylation in mutant LRRK2 pathological mechanism(s) and in LRRK2's response to inhibition, the mechanism by which this occurs is unknown. Therefore we aimed to identify the phosphatase for LRRK2. Using a panel of recombinant phosphatases, we found that PP1 (protein phosphatase 1) efficiently dephosphorylates LRRK2 in vitro. PP1 activity on LRRK2 dephosphorylation was confirmed in cells using PP1 inhibition to reverse LRRK2 dephosphorylation induced by the potent LRRK2 kinase inhibitor LRRK2-IN1 as well as in R1441G mutant LRRK2. We also found that PP1 and LRRK2 can form a complex in cells. Furthermore, we observed that PP1 inhibition modulates LRRK2's cellular phenotype by reducing skein-like LRRK2-positive structures associated with dephosphorylation. In conclusion, the present study reveals PP1 as the physiological LRRK2 phosphatase, responsible for LRRK2 dephosphorylation observed in PD mutant LRRK2 and after LRRK2 kinase inhibition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23937259      PMCID: PMC5141581          DOI: 10.1042/BJ20121772

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

Review 1.  The role of protein phosphatase-1 in the modulation of synaptic and structural plasticity.

Authors:  Richard P Munton; Sándor Vizi; Isabelle M Mansuy
Journal:  FEBS Lett       Date:  2004-06-01       Impact factor: 4.124

Review 2.  Kinases as targets for Parkinson's disease: from genetics to therapy.

Authors:  Renee Vancraenenbroeck; Evy Lobbestael; Marc De Maeyer; Veerle Baekelandt; Jean-Marc Taymans
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

Review 4.  What genetics tells us about the causes and mechanisms of Parkinson's disease.

Authors:  Olga Corti; Suzanne Lesage; Alexis Brice
Journal:  Physiol Rev       Date:  2011-10       Impact factor: 37.312

Review 5.  Phosphorylation of LRRK2: from kinase to substrate.

Authors:  Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

6.  Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.

Authors:  Christian Johannes Gloeckner; Karsten Boldt; Felix von Zweydorf; Sandra Helm; Ludwig Wiesent; Hakan Sarioglu; Marius Ueffing
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

7.  Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.

Authors:  Xianting Li; Qing Jun Wang; Nina Pan; Sangkyu Lee; Yingming Zhao; Brian T Chait; Zhenyu Yue
Journal:  PLoS One       Date:  2011-03-01       Impact factor: 3.240

8.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

9.  Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.

Authors:  Spencer B Hermanson; Coby B Carlson; Steven M Riddle; Jing Zhao; Kurt W Vogel; R Jeremy Nichols; Kun Bi
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  41 in total

Review 1.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 2.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 3.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

4.  C-terminally truncated, kidney-specific variants of the WNK4 kinase lack several sites that regulate its activity.

Authors:  Adrián Rafael Murillo-de-Ozores; Alejandro Rodríguez-Gama; Silvana Bazúa-Valenti; Karla Leyva-Ríos; Norma Vázquez; Diana Pacheco-Álvarez; Inti A De La Rosa-Velázquez; Agnieszka Wengi; Kathryn L Stone; Junhui Zhang; Johannes Loffing; Richard P Lifton; Chao-Ling Yang; David H Ellison; Gerardo Gamba; Maria Castañeda-Bueno
Journal:  J Biol Chem       Date:  2018-06-19       Impact factor: 5.157

5.  14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.

Authors:  Nicholas J Lavalley; Sunny R Slone; Huiping Ding; Andrew B West; Talene A Yacoubian
Journal:  Hum Mol Genet       Date:  2015-11-05       Impact factor: 6.150

Review 6.  Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.

Authors:  Andrew B West
Journal:  Exp Neurol       Date:  2017-07-29       Impact factor: 5.330

Review 7.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

Review 8.  Cellular processes associated with LRRK2 function and dysfunction.

Authors:  Rebecca Wallings; Claudia Manzoni; Rina Bandopadhyay
Journal:  FEBS J       Date:  2015-05-09       Impact factor: 5.542

9.  In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.

Authors:  Renée Vancraenenbroeck; Joren De Raeymaecker; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Arnout Voet; Veerle Baekelandt; Jean-Marc Taymans
Journal:  Front Mol Neurosci       Date:  2014-06-03       Impact factor: 5.639

10.  Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Authors:  Lauran Reyniers; Maria Grazia Del Giudice; Laura Civiero; Elisa Belluzzi; Evy Lobbestael; Alexandra Beilina; Giorgio Arrigoni; Rita Derua; Etienne Waelkens; Yan Li; Claudia Crosio; Ciro Iaccarino; Mark R Cookson; Veerle Baekelandt; Elisa Greggio; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2014-07-14       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.